WETS
SMMT icon

Wealth Enhancement Trust Services’s Summit Therapeutics SMMT Stock Holding History

Wealth Enhancement Trust Services’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Hold
81
– – ﹤0.01% 1089
2026
Q1 		$1.54K Buy
+81
New +$1.31K ﹤0.01% 704

Other funds holding SMMT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Wealth Enhancement Trust Services's SMMT Position: Q2 2026 in Review

Wealth Enhancement Trust Services held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 81 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Wealth Enhancement Trust Services first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.54K in Q1 2026. 155 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Wealth Enhancement Trust Services held 81 shares of Summit Therapeutics worth $1.18K as of Q2 2026.
  • Wealth Enhancement Trust Services left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1089 holding.
  • Wealth Enhancement Trust Services first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Wealth Enhancement Trust Services's Summit Therapeutics position peaked at $1.54K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.